Ibrutinib, the first-generation Bruton tyrosine kinase inhibitor, has well-documented cardiovascular effects that influence treatment decisions for patients with chronic lymphocytic leukemia. This quiz...
Ibrutinib, the first-generation Bruton tyrosine kinase inhibitor, has well-documented cardiovascular effects that influence treatment decisions for patients with chronic lymphocytic leukemia. This quiz...
Ibrutinib, the first-generation Bruton tyrosine kinase inhibitor, has well-documented cardiovascular effects that influence treatment decisions for patients with chronic lymphocytic leukemia. This quiz...
Ibrutinib, the first-generation Bruton tyrosine kinase inhibitor, has well-documented cardiovascular effects that influence treatment decisions for patients with chronic lymphocytic leukemia. This quiz...
A recent meta-analysis demonstrated that adherence to this dietary pattern is associated with an 11–30% reduction in the risk of cognitive impairment, dementia, and Alzheimer disease. This quiz will...